Document Detail


Quinolone action in Escherichia coli cells carrying gyrA and gyrB mutations.
MedLine Citation:
PMID:  8384139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have isolated spontaneous mutant strains of Escherichia coli KL16 showing different levels of nalidixic acid (NAL) resistance. From 40 independent mutants, 36 had gyrA and four had gyrB mutations. Most of the gyrA mutations (30/36) conferred high level NAL resistance. In contrast, the only gyrB mutation that conferred a relatively high level of NAL resistance also determined enhanced susceptibility to quinolones with a piperazinyl substituent at C7 position of the quinolone ring (amphoteric quinolones). This gyrB mutation (denoted gyrB1604), jointly with a gyrA mutation (denoted gyrA972) which confers a high level of quinolone resistance, were used to construct strain IC2476, carrying the two gyr mutant alleles. The susceptibility of this strain to amphoteric quinolones (pipemidic acid, norfloxacin and ciprofloxacin) was similar to that of the gyrA972 single mutant. This result indicates that the change in GyrA subunit which determines a high level of quinolone-resistance has the capacity to mask the hypersusceptibility to amphoteric quinolones promoted by the GyrB1604 mutant subunit. This capacity was further confirmed by studying the effects of ciprofloxacin (CFX) on gyrase inhibition in the gyrA972 gyrB1604 strain.
Authors:
G Herrera; V Aleixandra; A Urios; M Blanco
Related Documents :
17502409 - Dual targeting of dna gyrase and topoisomerase iv: target interactions of heteroaryl is...
16819959 - Real-time pcr detection of pseudomonas aeruginosa in clinical and municipal wastewater ...
18783019 - Comparison of the selection of antimicrobial resistance in fecal escherichia coli durin...
8737139 - Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates o...
22919639 - Evolutionary blueprint for host- and niche-adaptation in staphylococcus aureus clonal c...
15616329 - Genetic determinant of intrinsic quinolone resistance in fusobacterium canifelinum.
10884399 - Production of resistant hiv mutants during antiretroviral therapy.
16410039 - Extracellular trehalose utilization by saccharomyces cerevisiae.
17637919 - The persistence of fluoroquinolone-resistant campylobacter in poultry production.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  FEMS microbiology letters     Volume:  106     ISSN:  0378-1097     ISO Abbreviation:  FEMS Microbiol. Lett.     Publication Date:  1993 Jan 
Date Detail:
Created Date:  1993-04-20     Completed Date:  1993-04-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7705721     Medline TA:  FEMS Microbiol Lett     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  187-91     Citation Subset:  IM    
Affiliation:
Instituto de Investigaciones Citológicas, Fundación Valenciana de Investigaciones Biomédicas, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Infective Agents / pharmacology*
DNA Gyrase
DNA Topoisomerases, Type II / genetics*,  physiology
Drug Resistance, Microbial
Escherichia coli / drug effects*,  genetics
Microbial Sensitivity Tests
Mutation*
Nalidixic Acid / pharmacology
Structure-Activity Relationship
Chemical
Reg. No./Substance:
0/Anti-Infective Agents; 389-08-2/Nalidixic Acid; EC 5.99.1.-/DNA Gyrase; EC 5.99.1.3/DNA Topoisomerases, Type II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Injury and repair in biocide-treated spores of Bacillus subtilis.
Next Document:  Respective role of the 42- and 51-kDa components of the Bacillus sphaericus toxin overexpressed in B...